The Transgenic/Gene Knockout Shared Resource provides full project support for St. Jude investigators interested in developing faithful preclinical models of pediatric malignancies and other diseases. Our primary goal is to foster and accelerate the translation of promising therapeutic approaches into clinical trials for pediatric patients.
We employ six full-time technologists and offer services encompassing the full spectrum of techniques for the generation of GEMs, including CRISPR/Cas9- and TALEN-based genome editing approaches. The Transgenic/Gene Knockout Shared Resource has five injection rigs suitable for DNA, RNA, lentivirus and ES cell injections. Costs to investigators are offset by the institution.